|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 非诺贝特治疗与2型糖尿病患者长期心血管病风险的关系显示文摘2型糖尿病患者心血管病风险高,部分原因在于高三酰甘油和低高密度脂蛋白胆固醇血症。而在他汀类药物治疗基础上,加强降低三酰甘油治疗,能否降低这种风险尚不清楚。该研究的目的是在使用他汀类药物治疗的2型糖尿病患者中,确定非诺贝特能否降低心血管病风险。 | 刘莉 叶鹏 Elam MB Ginsberg HN Lovato LC Corson M Largay J Leiter LA Lopez C O'Connor PJ Sweeney ME Weiss D Friedewald WT Buse JB Gerstein HC Probstfield J Grimm R Ismail-Beigi F Goff DC Jr Fleg JL Rosenberg Y Byington RP ACCORDION study investigators | 2017 | 中华高血压杂志2017，25，6： | 7 |
| 2 | Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)显示文摘 | Inzucchi Silvio E Bergenstal Richard M Buse John B Diamant Michaela Ferrannini Ele Nauck Michael Peters Anne L Tsapas Apostolos Wender Richard Matthews David R | 2012 | EN2012，，3： | 6 |
| 3 | Glucose-responsive oral insulin delivery for postprandial glycemic regulation显示文摘Controlling postprandial glucose levels for diabetic patients is critical to achieve the tight glycemic control that decreases the risk for developing long-term micro- and macrovascular complications.Herein,we report a glucose-responsive oral insulin delivery system based on Fc receptor (FcRn)-targeted liposomes with glucose-sensitive hyaluronic acid (HA) shell for postprandial glycemic regulation.After oral administration,the HA shell can quickly detach in the presence of increasing intestinal glucose concentration due to the competitive binding of glucose with the phenylboronic acid groups conjugated with HA.The exposed Fc groups on the surface of liposomes then facilitate enhanced intestinal absorption in an FcRn-mediated transport pathway.In vivo studies on chemically-induced type 1 diabetic mice show this oral glucose-responsive delivery approach can effectively reduce postprandial blood glucose excursions.This work is the first demonstration of an oral insulin delivery system directly triggered by increasing postprandial glucose concentrations in the intestine to provide an on-demand insulin release with ease of administration. | Jicheng Yu Yuqi Zhang Jinqiang Wang Di Wen Anna R. Kahkoska John B. Buse Zhen Gu | 2019 | Nano Research2019，12，7： | 6 |
| 4 | 每日1次利拉鲁肽与每日2次艾塞那肽治疗2型糖尿病比较:一项为期26周的随机、平行组、多国开放标记试验(LEAD-6)显示文摘背景与大多数抗高血糖药物不同,胰高血糖素样肽-1(GLP-1)受体激动剂的药理作用依赖于葡萄糖水平,并且有助于减轻患者体重。本研究比较了利拉鲁肽(一种人GLP-1类似物)与艾塞那肽(一种基于醋酸艾塞那肽的GLP-1受体激动剂)治疗2型糖尿病的疗效和安全性。方法对于用最大耐受剂量二甲双胍或(和)磺脲仍控制不良的2型糖尿病成年患者,根据之前服用的抗糖尿病药物进行分层,并随机分配这些患者额外接受利拉鲁肽1.8mg每El1次(n=233)或艾塞那肽10μg每日2次(n=231),进行为期26周的开放标记、平行组、多国(15个国家)研究。主要终点是糖化血红蛋白(HbA1c)水平的变化,疗效分析采用意向性治疗分析。本试验在Clinical Trial.gov注册,注册号为NCT00518882。结果受试者的HbA1c平均基线水平为8.2%。与艾塞那肽相比,利拉鲁肽能显著降低HbA1c平均水平[-1.12%(s=0.08%)vs-0.79%(s=0.08%);疗效差异估计值为-0.33%,95%CI-0.47%~-0.18%;P〈0.0001],并且利拉鲁肽组有更多患者HbA1c水平低于7%(54%vs543%;OR 2.02,95%CI 1.31~3.11;P=0.0015)。利拉鲁肽降低平均空腹血糖的能力也显著优于艾塞那肽[-1.61mmol/Lb=0.20)vs-0.60mmol/L(s=0.20);疗效差异估计值为-1.01mmol/L,95%CI-1.37—-0.65;P〈0.0001],但是其降低早餐和晚餐后血糖的能力较艾塞那肽差。两种药物促进患者体重减轻的作用相似(利拉鲁肽组~3.24kg vs艾塞那肽组-2.87地)。耐受性均较好,但与艾塞那肽组相比,利拉鲁肽组患者恶心的持续时间较短(估计的治疗相关事件率比值为0.448,P〈0.0001),轻度低血糖的发生率也较低(每患者每年的事件发生数为1.93vs2.60;发生率比值为0.55,95%C10.34~0.88:P=0.0131;轻度低血糖的发生率为25.5%掷33.6%)。2例同时注射艾塞那肽和一种磺脲类药物的患者发生了严重的低血糖。结论相对于艾塞那肽每日2次,利拉鲁肽每日1次能显著改善血糖控制水平,且患者的耐受性更好。研究结果提示利拉鲁肽或许是2型糖尿病的一种治疗选择,特别是在减轻体重和低血糖风险作为主要考虑因素的情况下。 | John B Buse Julia Rosenstock Giorgio Sesti Wolfgang E Schmidt Eduard Montanya Jason H Brett Marcin Zychma Lawrence Blonde 赵乐(译) | 2009 | 世界临床医学2009，，11： | 3 |
| 5 | 2型糖尿病高血糖的起始和调整治疗共识——美国糖尿病学会和欧洲糖尿病研究协会联合共识显示文摘专家点评:在2005年欧洲糖尿病研究协会(EASD)年会上,国际糖尿病联盟(IDF)颁布了全球首个2型糖尿病治疗指南,我国也发布了自己的指南,然而无论哪个指南,其中主要部分是参考欧美主持的全球多中心临床研究结果。糖尿病药物研究近些年进展迅速,即使在指南的范畴内,仍然有很多选择,令临床医生难以取舍。本文编译介绍了现阶段各种用于2型糖尿病治疗的药物,结合临床研究结果,突出其各自临床应用的优缺点;同时,在药物联合使用和进阶治疗方面,介绍了具体的实施方案和流程,为临床达标治疗的用药选择提供了实用的参考。 | Nathan DM Buse JB Davidson MB 华雪蔚 | 2007 | 世界临床药物2007，28，6： | 3 |
| 6 | Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial显示文摘 | Simon Heller John Buse Miles Fisher Satish Garg Michel Marre Ludwig Merker Eric Renard David Russell-Jones Areti Philotheou Ann Marie Ocampo Francisco Huiling Pei Bruce Bode | 2012 | The Lancet2012，，9825： | 2 |
| 7 | LED-pumped whispering-gallery laser显示文摘A low-cost light-emitting diode(LED) is sufficient to pump a quasi-continuous-wave bidirectional high-Q whispering-gallery resonator laser made of Nd:YVO_4. This is remarkable because of the very limited spatial and spectral coherence of an LED. The LED, delivering up to 3.5 W, centered around 810 nm, is turned on in intervals of 100 μs duration, and for these periods a laser output exceeding 0.8 mW has been verified.Furthermore, 0.1-s-long laser pulses are demonstrated. To the best of our knowledge, this is the first demonstration of an LED-pumped high-Q whispering-gallery laser. The concept can be extended easily to other laser active materials. A prospect is also to pump several of such lasers with a single LED. | SIMON J.HERR KARSTEN BUSE INGO BREUNIG | 2017 | Photonics Research2017，5，6： | 2 |
| 8 | Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)显示文摘 | John B Buse Julio Rosenstock Giorgio Sesti Wolfgang E Schmidt Eduard Montanya Jason H Brett Marcin Zychma Lawrence Blonde | 2009 | The Lancet2009，，9683： | 2 |
| 9 | Medical management of hyperglycemia in type 2 diabetes:a consensus algorithm for the initiation and adjustment of therapy:a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes显示文摘 | Nathan DM Buse JB Davidson MB | | Diabetes Care0，，： | 2 |
| 10 | ADA与EASD对2型糖尿病高血糖处理:治疗启动与评定的新共识方案显示文摘在不到一年时间由同一批专家代表ADA和EASD先后起草和发布了两次关于'2型糖尿病高血糖处理的共识声明'同时发表在2008年1月和12月的《Diabetes Care》和《Diabetologia》上。第一次共识声明内容主要围绕TZDs药物的安全性,本刊作了摘译转载(参阅《中国糖尿病杂志》2008年第7期)。第二次修订的共识声明,关注点为降糖药的新分级,论据及观点比较清晰,故仍摘译供读者参考。 | Nathan DM Buse JB Davidson MB Ferrannini E Holman RR Sherwin R Zinman B 钱荣立(摘译) | 2009 | 中国糖尿病杂志2009，17，1： | 2 |
| 11 | Two step photorefractive hologram recording in LiNbO 3:Fe显示文摘 | BUSE K JERMANN F KRATZIG E | 1993 | Ferroelectrics1993，141，： | 2 |
| 12 | Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study显示文摘 | Daniel J Drucker John B Buse Kristin Taylor David M Kendall Michael Trautmann Dongliang Zhuang Lisa Porter | 2008 | The Lancet2008，，9645： | 2 |
| 13 | Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)显示文摘 | S. E. Inzucchi R. M. Bergenstal J. B. Buse M. Diamant E. Ferrannini M. Nauck A. L. Peters A. Tsapas R. Wender D. R. Matthews | 2012 | Diabetologia2012，，6： | 2 |
| 14 | Glucagon like peptide l-based therapies for type 2 diabetes: a focus on exenatide显示文摘 | Dungan K Buse JB | 2005 | Clin Diabetes2005，23，： | 1 |
| 15 | The metabolic syndrome:time for a criticaL appraisal:joint statement from the American Diabetes Association and the European Association for the Study of Diabetes 显示文摘 | Kahn R Buse J Ferrannini E | 2005 | Diabetes Care2005，28，9： | 1 |
| 16 | Fenofibrate -associ- ated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes : the Action to Control Car- diovascular Risk in Diabetes (ACCORD) experience 显示文摘 | BONDS D E CRAVEN T E BUSE J | 2012 | Diabe- tologia2012，55，6： | 1 |
| 17 | Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association 显示文摘 | Buse JB Ginsberg HN Bakris GL | 2007 | Circulation2007，115，1： | 1 |
| 18 | Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy显示文摘 | Nathan D M Buse J B Davidson M B | 2008 | Diabetologia2008，16，51： | 1 |
| 19 | Behavioral medicine for migraine显示文摘 | Buse DC Andrasik F | 2009 | Neurol Clin2009，27，2： | 1 |
| 20 | medical management of hyperglycaemia in type 2 diabetes mellitus:a consensus algorithm for the initiation and adjustment of therapy:a consensus statement from the American Diabetes Association and the European Association for the study of diabete显示文摘 | Nathan DM Buse JB Davidson MB | 2009 | Diabetologia2009，52，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员